RFG
CTXR icon

REAP Financial Group’s Citius Pharmaceuticals CTXR Stock Holding History

REAP Financial Group’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11
Closed -$214 – 609
2023
Q4 		$214 Buy
+11
New +$209 ﹤0.01% 633

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

REAP Financial Group's CTXR Position: Q1 2024 in Review

REAP Financial Group sold out of Citius Pharmaceuticals (CTXR) in Q1 2024, closing a stake of 11 shares — an estimated $214 sold.

REAP Financial Group first reported a position in CTXR in Q4 2023 and held it in 1 quarter. The position peaked at $214 in Q4 2023. 73 funds tracked by Wall St. Rank hold CTXR as of Q1 2024.

  • REAP Financial Group reported no remaining Citius Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • REAP Financial Group sold 11 Citius Pharmaceuticals shares in Q1 2024, an estimated $214.
  • REAP Financial Group first reported a position in Citius Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • REAP Financial Group's Citius Pharmaceuticals position peaked at $214 in Q4 2023.
  • 73 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2024.

Based on REAP Financial Group's 13F filing for Q1 2024, filed 27 Feb 2025.